Application of "I-Anticoagulation"in Patients With Atrial Fibrillation

Launched by RENJI HOSPITAL · Nov 14, 2023

Keywords

ClinConnect Summary

This clinical trial is designed to study a new tool called "I-Anticoagulation" that helps doctors and patients make better decisions about anticoagulant treatments for people with atrial fibrillation (AF), a condition where the heart beats irregularly. The trial aims to find out if this decision-making tool can lead to more effective use of anticoagulants, which are medications that help prevent blood clots, and whether it can improve patient satisfaction and adherence to their treatment plans. Participants in this study will be compared to a control group that receives standard care without the tool.

To be eligible for the trial, participants need to be 18 years or older and have been newly diagnosed with AF, confirmed by specific heart tests. They must also be willing to join the study and sign a consent form. However, people who are pregnant, have certain serious health issues, or have had recent bleeding complications won't be able to participate. Those who join the trial can expect to work closely with healthcare providers using the "I-Anticoagulation" tool throughout their treatment. This study is important because it aims to improve how patients with AF are managed and may lead to better health outcomes for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients who are 18 years or older and have received a new diagnosis of paroxysmal, persistent, or permanent AF confirmed by electrocardiogram (ECG) or 24-hour Holter monitors
• • must be willing to participate in the study and sign the informed consent
• Exclusion Criteria:
• • those who are pregnant
• • those whohave experienced therapeutic or subtherapeutic bleeding complications in the last 6 months
• • those who have severe renal insufficiency (creatinine clearance rate, CrCl ≤ 20 ml/min)
• • those who have severe hepatic insufficiency (Child-Pugh ≥ 10 points)
• • those who have severe heart failure (cardiac function New York Heart Association, NYHA grade IV and above)
• • those who have severe infection and respiratory failure
• • those who are unable to comply with the study requirements.